These findings suggest that there is a narrow window or ‘sweet spot’ of oncogenic RAS signalling conducive to tumour formation; too much leads to abortive processes like growth arrest, and too little ...
At the moment, RevMed remains keenly focused on its mission to bring daraxonrasib to the masses and continue developing new medicines that target RAS. (Darren Incorvaia) This year’s meeting of the ...
An investigational oral drug that targets RAS, the dominant oncogenic driver in pancreatic cancer, nearly doubled overall survival compared with common second-line chemotherapy regimens in patients ...
The Higher Education Commission has launched PhD Country Directory Online System for the benefit of PhD scholars. It was inaugurated by Minister for Federal Education and Professional Training Rana ...
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a class of drugs used to treat type 2 diabetes and, in some cases, obesity. GLP-1 RAs are very effective at lowering blood sugar levels. As an ...
UK's FTSE 100 climbs on earnings boost, midcaps jump after BoE rate hold London's FTSE 100 index rose on Thursday, with upbeat results from Rolls-Royce and Glencore bolstering sentiment, while ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results